YM BioSciences closes nimotuzumab trials in North America
Nimotuzumab, a humanized monoclonal antibody targeting EGFR, is indicated for the patients with brain metastasis from non-small cell lung cancer (NSCLC) and palliative treatment of NSCLC. YM BioSciences
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.